Rheumatic Fever Market Overview
The global rheumatic fever market is witnessing a rapid increase in revenues. Market growth is attributed to the rising prevalence of rheumatic fever and the development of many breakthrough drugs and therapeutics. Besides, factors such as the increasing government expenditure for the healthcare sector contribute to market growth. Moreover, COVID 19 pandemic is expected to escalate the market growth to furthered heights during the estimated period. Market Research Future analyses the market is emerging at a healthy CAGR as a massive investment in research and development are the factors becoming responsible for the growth of this market.
Rheumatic fever is caused by an incorrectly treated strep throat, which can cause complications such as rheumatic fever. Rheumatic fever is an autoimmune disease and can cause lasting damage to the heart and heart valves. The growing prevalence of strep throat is a major driver for the global rheumatic fever market over the forecast period. Increasing prevalence of rheumatic heart disease is also a major driver for the global rheumatic fever market over the forecast period. Rheumatic fever is mostly seen in the age group of 5 to 15 years, however, adults may also sometimes contract the disease. Lack of awareness about Rheumatic Fever Market Size especially in developing countries, is likely to be a key restraint against the global rheumatic fever market over the forecast period. The limited healthcare facilities in developing countries are also a major restraint on the market.
The department of Economic and Social Affairs in the year 2017 stated that the global population aged 60 years and above was around 901 million, which is likely to mount drastically in the estimated period. The population aged fifty years and above has the most significant incidence of rheumatic disease and mortality rates as compared to younger people. The incidence rate of rheumatic fever is elevated in developing countries as compared to that in developed countries. As per the Centers for Disease Control and Prevention (CDC), regarding 23% of adults in the U.S., which is above 54 million people, suffer arthritis. By the year 2040, the disease might affect 78 million adults in the country. Rheumatic fever is a primary cause of disability. The direct medical costs linked with the disease are above US$ 81 Mn annually. This disease is common in women over men.
Rheumatic Fever Market Segmentation
· The global rheumatic fever market is segmented on the basis of diagnosis, treatment, distribution channel, end user, and region.
· By diagnosis, the global rheumatic fever market is segmented into physical exam, blood test, electrocardiogram, and echocardiogram.
· By treatment, the global rheumatic fever market is segmented into pharmacotherapy and others. The pharmacotherapy segment is further sub-segmented into antibiotics, anti-inflammatory medication, anticonvulsant medication, and others. The anti-inflammatory medication segment is further sub-segmented into aspirin, naproxen, and others. The anti-inflammatory medication segment is likely to hold a dominant share in the global rheumatic fever market over the forecast period, due to the highly effective results obtained by the use of anti-inflammatory medication. Anti-inflammatory medication controls the body’s immune system and reduces its impact. This makes the rheumatic fever weaker and unable to proliferate. This is likely to drive the share of the anti-inflammatory medication segment in the global rheumatic fever market over the forecast period.
· By distribution channel, the global rheumatic fever market is segmented into retail pharmacies, hospital pharmacies, and others. Both retail and hospital pharmacies are likely to hold an important share in the global rheumatic fever market over the forecast period. The increasing spread of retail pharmacies in developing regions is likely to remain a key driver for the segment over the forecast period.
· By end user, the global rheumatic fever market is segmented into hospitals and clinics, diagnostic centers, and others. The hospitals and clinics segment dominates the global rheumatic fever market and is likely to hold the largest share in the global market over the forecast period.
Rheumatic Fever Market Regional Analysis
North America has been witnessing an optimistic growth for the rheumatic fever market throughout the forecasted period owing to the elevated prevalence of rheumatic fever and the occurrence of sophisticated medical facilities to optimize the treatment for patients suffering from rheumatic fever.
Europe is considered the second-largest mounting regional segment due to the key-marketed players and surges focus on the research and development activity.
Asia-Pacific leads the market owing to the developing healthcare facilities, a significant number of generic manufacturers and an increase in government initiatives and specialist communities.
North America led the global rheumatic fever treatment market, in support of surge in the geriatric population and a mount in the prevalence of rheumatic fever in the region.
Rheumatic Fever Market Players
- Bayer AG
- Abbott Laboratories
- Johnson & Johnson Services, Inc.
- Hoffman-La Roche Ltd.
- Novartis AG
- Pfizer, Inc
- AstraZeneca
- Valeant Pharmaceuticals International, Inc
- Eli Lily
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/rheumatic-fever-market-6310
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
